Impact of SGLT2 inhibitors on cardiac function and infarct size in experimental myocardial ischemic injury: systematic literature review and meta-analysis

Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have been included in current clinical practice guidelines to decrease heart failure hospitalization or cardiovascular death, but further rigorous studies are necessary to determine the extent of their capacity for managing HF symptoms. We carried out a systematic literature review and meta-analysis to evaluate the impact of different SGLT2i on left ventricular ejection fraction (LVEF) and/or infarct size (IS) measured as the % of either the left ventricle (LV) or the area at risk (AAR) in animal models of myocardial infarction and ischemia–reperfusion injury. The study protocol was pre-registered in the International Prospective Register of Systematic Reviews (PROSPERO, CRD42023427960). PubMed, Scopus and Web of Science databases were searched from inception to 15 May 2025. Primary endpoints were changes to LVEF and IS in treated versus control groups. Sixty-five studies with a total of 99 valid comparisons complying with the pre-defined inclusion criteria were identified. SGLT2i-treated animals exhibited a significantly improved LVEF (MD = 11.25% [95% CI 9.45, 13.05], p < 0.0001) and decreased IS both when measured as a %LV (MD = − 11.57% [95% CI − 14.96, − 8.18], p < 0.0001) or as a %AAR (MD = − 15.47% [95% CI − 19.03, − 11.91], p < 0.0001) compared to control subjects, independently of diabetic status. A sex-specific meta-analysis revealed a potentially greater LVEF improvement in males (MD = 12.08% [95% CI 10.14; 14.01]) than females (MD = 7.27% [95% CI 4.52; 10.03], p = 0.03). Dapagliflozin administration decreased IS as a %LV significantly more than empagliflozin (MD = − 15.99 [95% CI − 20.64, − 11.35] versus MD = − 4.14 [95% CI − 11.46, − 3.18], p = 0.013). In conclusion, the use of SGLT2i in animal models of ischemia improves LVEF irrespective of the SGLT2i used or the diabetic status of the subjects, significantly more in male animals, and consistently decreases IS.

Authors

Institutions

Publication Details

Journal
European journal of medical research
Published
2026-05-18
DOI
https://doi.org/10.1186/s40001-026-04557-9
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of SGLT2 inhibitors on cardiac function and infarct size in experimental myocardial ischemic injury: systematic literature review and meta-analysis

Claudia Báez-Díaz, Verónica Crisóstomo, Fátima Vázquez-López, Axiel Torrescusa-Bermejo et al.
European journal of medical research
Diabetes Treatment and Management
article

Impact of SGLT2 inhibitors on cardiac function and infarct size in experimental myocardial ischemic injury: systematic literature review and meta-analysis

Claudia Báez-Díaz, Verónica Crisóstomo, Fátima Vázquez-López, Axiel Torrescusa-Bermejo, Luisa F. Sánchez-Peralta, F M Sanchez-Margallo, C Galvez-Monton
article en

Abstract

Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have been included in current clinical practice guidelines to decrease heart failure hospitalization or cardiovascular death, but further rigorous studies are necessary to determine the extent of their capacity for managing HF symptoms. We carried out a systematic literature review and meta-analysis to evaluate the impact of different SGLT2i on left ventricular ejection fraction (LVEF) and/or infarct size (IS) measured as the % of either the left ventricle (LV) or the area at risk (AAR) in animal models of myocardial infarction and ischemia–reperfusion injury. The study protocol was pre-registered in the International Prospective Register of Systematic Reviews (PROSPERO, CRD42023427960). PubMed, Scopus and Web of Science databases were searched from inception to 15 May 2025. Primary endpoints were changes to LVEF and IS in treated versus control groups. Sixty-five studies with a total of 99 valid comparisons complying with the pre-defined inclusion criteria were identified. SGLT2i-treated animals exhibited a significantly improved LVEF (MD = 11.25% [95% CI 9.45, 13.05], p < 0.0001) and decreased IS both when measured as a %LV (MD = − 11.57% [95% CI − 14.96, − 8.18], p < 0.0001) or as a %AAR (MD = − 15.47% [95% CI − 19.03, − 11.91], p < 0.0001) compared to control subjects, independently of diabetic status. A sex-specific meta-analysis revealed a potentially greater LVEF improvement in males (MD = 12.08% [95% CI 10.14; 14.01]) than females (MD = 7.27% [95% CI 4.52; 10.03], p = 0.03). Dapagliflozin administration decreased IS as a %LV significantly more than empagliflozin (MD = − 15.99 [95% CI − 20.64, − 11.35] versus MD = − 4.14 [95% CI − 11.46, − 3.18], p = 0.013). In conclusion, the use of SGLT2i in animal models of ischemia improves LVEF irrespective of the SGLT2i used or the diabetic status of the subjects, significantly more in male animals, and consistently decreases IS.

European journal of medical research
Instituto de Salud Carlos III (ES), Centro de Investigación en Red en Enfermedades Cardiovasculares (ES), Centro de Cirugía de Mínima Invasión Jesús Usón (ES), Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (ES)
Good health and well-being
Openalex Percentile: Top 6%
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.